Latest news with #ApolloCancerCentres
Time of India
16 hours ago
- Health
- Time of India
Apollo Cancer Centres launches early detection program for women's cancers
New Delhi: Apollo Cancer Centres (ACCs) has launched End-O Check , an early detection program for women aged 45 and above. The initiative is indicated to focus on identifying endometrial and ovarian cancers—two of the most common gynaecologic cancers —at an early, more treatable stage. The program aims to raise awareness of symptoms, support timely diagnosis in high-risk groups, and promote preventive care, encouraging women to take proactive measures for their gynaecologic health. Dr Pakhee Agarwal, Senior Consultant – Gynaecology Oncology & Robotic Surgery, Apollo Cancer Centre, New Delhi, said, ' Endometrial cancer has been on the rise in women above the age of 45 years, so early detection is crucial for better outcomes. Global data indicates a five years survival rate of around 96 per cent for localized disease. However, survival rates drop substantially when diagnosis is delayed, underscoring the importance of timely detection. Key risk factors include obesity, diabetes, early menstruation, late menopause, and polycystic ovary syndrome (PCOS), all of which are becoming more prevalent among Indian women.' Dr. Reeti, Senior Consultant, Radiology Department, Apollo Cancer Centre, New Delhi, said, 'Radiology plays a crucial role in the early detection of gynaecologic cancers . Through End-O Check, we are integrating transvaginal ultrasonography (TVS) as the diagnostic tool to help identify subtle changes that could indicate early-stage ovarian or endometrial cancers. Early imaging intervention allows clinicians to act promptly, improving treatment options and outcomes for patients."
Time of India
01-08-2025
- Health
- Time of India
Apollo Cancer Centres Launches Early Detection program for Gynaecological Cancers
Bangalore: Apollo Cancer Centres (ACCs) has launched End-O Check , an early detection programme aimed at women aged 45 and above, focusing on endometrial and ovarian cancers. The two gynaecological cancers are among the most common and often go undetected until advanced stages. According to the hospital, End-O Check is intended to support early identification in higher-risk populations, increase symptom awareness, and enable timely clinical intervention. The initiative is intended to encourage women to be proactive in monitoring their gynaecologic health. Dr. Aruna R Patil, Senior Consultant and Head of Department of Radiology, Apollo Cancer Centre, Bangalore, said, 'Radiology plays a crucial role in the early detection of gynaecologic cancers. Through End-O Check, we are integrating transvaginal ultrasonography (TVS) as the diagnostic tool to help identify subtle changes that could indicate early-stage ovarian or endometrial cancers. Early imaging intervention allows clinicians to act promptly, improving treatment options and outcomes for patients."
Time Business News
25-07-2025
- Health
- Time Business News
Breakthrough Innovations Transforming Lung Cancer Diagnosis and Treatment
Lung cancer is a type of cancer that begins in the lungs, often caused by smoking, exposure to pollutants, genetic factors or commercial threats. Lung cancer market is increasing due to growing global lung cancer rate, awareness and increase in screening programs, progress in clinical technologies (such as low -dosage CT scans and liquid biopsy) and increasing remedies and development of targeted remedies and immunotherapy. Additionally, better healthcare in aging population and emerging areas is promoting infrastructure and early detection and demand for effective treatment solutions. Key Growth Drivers and Opportunities Growing Global Lung Cancer Rate: Rising global lung cancer rate is a major driver of lung cancer market development, as it increases the demand for early identity, accurate diagnosis and effective treatment solutions. One of the major causes of cancer-related deaths worldwide with lung cancer, healthcare systems are making heavy investments in advanced screening tools such as low-dosage CT scans and biomarker-based diagnosis to enable the first diagnosis. At the same time, rising patient numbers are accelerating the development and adoption of innovative remedies including targeted drugs and immunotherapy. The burden of growing disease also attracts more research funds and industry investment, further fuel to market expansion. Challenges The lung cancer market faces several borders, including advanced diagnosis and high cost of targeted treatments, which can limit access to areas with especially low and moderate income. Delayed diagnosis also disrupts the results of treatment due to lack of awareness, limited screening programs and non-specific initial symptoms. Additionally, the challenge of complex regulatory routes, delayed stage patients, and the challenge of managing side effects from therapy disrupts the market growth despite technological progress. Innovation and Expansion EQUAL Study Launches High-Risk Group Lung Cancer Screening Trial In May 2025, Researchers at the Dana-Farber Cancer Institute have begun testing a new, in-house blood test in an effort to screen for lung cancer and identify those who are at a higher risk of developing the disease even if they have never used tobacco. Epidermal growth factor receptor (EGFR) gene mutations can be common in the Asian and Hispanic/Latinx populations, which is the subject of the EQUAL (EGFR ctDNA Quantitative Assessment for Lung Cancer screening in Asian and Latinx populations) study. Possessing this mutation increases the risk of lung cancer because EGFR type mutations are linked to the illness. Additionally, the number of cancer diagnoses among Asian or Hispanic/Latinx individuals is increasing at a faster rate. With India's First LungLife Screening Program to Fight Lung Cancer, Apollo Cancer Centre Sets the Standard In March 2025, India's first LungLife Screening Program for early lung cancer diagnosis has been introduced by Apollo Cancer Centres (ACCs), a pioneer in state-of-the-art cancer care. Lung cancer, which makes up 5.9% of all malignancies and 8.1% of cancer-related deaths in India, is the target of this ground-breaking project. Early identification increases the survival rate and improves treatment results (LINK). Low-dose computed tomography (LDCT) early screening can greatly increase survival chances and help with early diagnosis. However, almost 80% of high-risk patients have never spoken to their doctors about screening. To allow early detection and save lives, it is imperative to improve knowledge and communication regarding lung cancer screening, particularly among high-risk individuals. Inventive Sparks, Expanding Markets The key players operating the lung cancer market include AstraZeneca, Hoffman La Roche, Eli Lilly and Company, Pfizer Inc., Merck & Co., Amgen Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb Company. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Time of India
25-06-2025
- Health
- Time of India
Apollo Cancer Centres launches 'CanWin' support group
New Delhi: Apollo Cancer Centres (ACCs) has launched 'CanWin', a cancer support group aimed at creating a shared space for patients, survivors, caregivers, oncologists, and volunteers. The initiative is In recognition of National Cancer Survivors Month. According to ACCs, CanWin is a brand-agnostic platform focused on providing emotional support and community-based healing. The initiative aims to bring together various stakeholders in the cancer journey—including psycho-oncologists and healthcare professionals—to offer guidance, empathy, and shared experiences. The group is intended to be a space to talk, listen, and heal, whether someone is recently diagnosed, undergoing treatment, or living beyond cancer. The initiative was launched with a storytelling session led by cancer survivors, who shared personal narratives of their journeys. The event also included professional storytellers who mentored participants in using their stories as a tool for healing and connection. Oncologists attending the launch emphasized the improvement in cancer survival rates across age groups, especially with early detection and advances in treatment. They noted that initiatives like CanWin contribute to emotional recovery and enhance quality of life during and after treatment. It is stated that the CanWin support group will offer monthly gatherings, storytelling therapy , survivor-led workshops, expert Q&A sessions, and volunteer opportunities.
The Hindu
25-06-2025
- Health
- The Hindu
Apollo Cancer Centres launches ‘CanWin' to support patients, survivors, and caregivers
Apollo Cancer Centres (ACC) has launched CanWin, a cancer support group designed to provide structured emotional and psychological support to patients, survivors, caregivers and healthcare professionals. Unveiled during National Cancer Survivors Month, the initiative aims to complement clinical treatment with survivor-led guidance, therapy-based storytelling and open dialogue. The launch event began with survivors sharing their personal narratives of treatment, recovery and coping. A 10-year-old Medulloblastoma survivor from Chennai shared his experience, starting with how a routine check-up led to answers for many of his symptoms. A Hodgkin lymphoma survivor spoke about her delayed diagnosis and complex treatment journey. 'Just months after giving birth, I discovered a lump — first mistaken for tuberculosis. What followed were relapses, five lines of chemotherapy, a bone marrow transplant and 35 rounds of radiation. I missed my child's early years, but I came through with the support of my family and medical team,' she said. Priyanka Bagdi, a leukemia survivor, doctor and author of a book about her experience, spoke about her prolonged hospital stays and the emotional toll of treatment. Experts at the event stressed that while clinical outcomes are improving with advanced diagnostics and early detection, stigma around cancer screening and diagnosis remains a significant barrier. In a panel discussion that followed they called for urgent efforts to normalise conversations around diagnostic tools and to strengthen psychosocial support within cancer care. The programme will continue through monthly support group meetings, survivor-led workshops, expert sessions and volunteering opportunities.
